Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan + amoxicillin + nitazoxanide versus non-bismuth quadruple therapy for first-line Helicobacter pylori eradication
PACTR202605705734927Phase 4Recruiting
- Sponsor
- Aburrahman N. And Marwa E.
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of vonoprazan, amoxicillin and nitazoxanide in Helicobacter pylori infection (2 arms), sponsored by Aburrahman N. And Marwa E. Primary endpoint: Helicobacter pylori eradication rate. Started Feb 2026; status: recruiting.
02
Drugs
vonoprazanamoxicillinnitazoxanide
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on PACTR202605705734927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605705734927.